Twenty two patients with exacerbation of inflammatory bowel disease (19 with Crohn's disease, 3 with ulcerative colitis) and thrombocytosis were tested for possible activation of the coagulation and platelet system.
Introduction
. . also reports on the occurrence of thrombocytosis in As we know from the literature (1 -3) thromboem-the exacerbation phase of inflammatory bowel disbolism is an accepted complication of inflammatory ease. Until the present work, however, no data were bowel disease. In the acute phase, F VIII, F II, fibri-available on the functional state of platelets in the nogen, plasminogen, prekallikrein and high molecular acute phase of inflammatory bowel disease. We thereweight kallikrein are enhanced, which could account fore investigated the in vitro aggregation activity of for thromboembolic complications (4 -7) . No evi-the thrombocytes. For the investigation of the state dence has been reported, however, for a prethrom-of the coagulation system we determined fibrinogen, botic state in the stable phase of chronic inflammatory the fibrin monomer concentration and the thrombinbowel disease (8) . Recent research on the changes in antithrombin III complex. For the investigation of parameters of the fibrinolysis system in the peripheral fibrinolysis we chose the recently developed ELISAblood of patients with inflammatory bowel disease assay for the D-Dimer. has shed some light on the nature and magnitude of the disturbances of fibrinolysis and their relationship ^M . _ , m m . , /ηλ , -, .
, ' -u . (9) to the development of deep venous thrombosis. There is evidence for a decrease in tissue plasminogen Patients activator as well as an increase in plasminogen acti-Plasma samples were collected from 22 patients (16 3 patients with ulcerative colitis. The activity index of van Hees (11) ranged from 210 -313. The use of medication was excluded. All the female patients were using oral contraceptive drugs. The main inclusion criterium from the laboratory point of view was the presence of a thrombocytosis. A reference group consisted of subjectively healthy individuals from the hospital and laboratory staff.
Materials and Methods

Samples
For the platelet count, venous blood was collected in plastic vials containing 1.6 g/1 EDTA-K 2 (Sarstedt, Numbrecht, FRG). Samples were kept between 30 min and 4 hours at room temperature until analysis.
Coagulation parameters were determined in titrated plasma, prepared by centrifugation of nine volumes freshly drawn blood with one volume trisodium titrate (0.11 mol/1) for 10 min (1600g) at 25 °C. The plasma was stored at -70 °C in plastic tubes and thawed with tap water for 5 min before serial analysis.
The platelet aggregation test was performed on platelet rich plasma, which was prepared by immediate centrifugation of citrated blood (prepared as described above) at 200 g for 10 minutes at room temperature. After gentle aspiration of the platelet-rich plasma, using a plastic pipette, the remaining blood was centrifuged at 2000 # for 10 min at room temperature; the resulting platelet-poor plasma was aspirated and subsequently centrifuged at 10 000 g at 4 °C for 10 min to obtain plateletfree plasma. Platelet-rich plasma and platelet-free plasma were used for standardization of the end concentration of the platelet count in the test. The collagen-induced aggregation was performed at a thrombocyte concentration of 400 χ 10 9 /1, whereas the other induced aggregations were performed at a platelet concentration of 200 χ 10 9 /1· The spontaneous (i.e. induced by stirring alone) aggregation was carried out in platelet-rich plasma.
Methods
Platelets were counted with a Sysmex E-4000 (Kobe, Japan) cell counter. Platelet aggregation was measured by a turbidimetric method using a Daiichi dual channel aggregation device. The test concentrations of the different inducing agents are quoted in the results. Fibrinogen was determined by the clotting assay of Clauss. The FM test is a semi-quantitative test from the Boehringer Mannheim Corp (FRG), using fibrinogencoated erythrocytes to detect circulating fibrin monomers in plasma (detection level 10 mg/1). Thrombin-antithrombin III was determined with an ELISA test kit (Behring Corporation, Marburg, FRG). D-Dimer was assayed in plasma with an ELISA method (Boehringer Mannheim. FRG).
Results
Values for the coagulation and fibrinolysis parameters are presented in table 2. Close agreement between the mean and median value was observed only in the case of fibrinogen (5.6 and 5.8 g/1 respectively). In the case of the platelets, fibrinogen, thrombinantithrombin III and D-Dimers, the sex differences were statistically significant. Table 6 shows the comparison of values for male patients and for female patients with those for the reference group. Highly significant differences were found between the mean values of parameters from male or female patients and those of the reference group, with the exception of the thrombin-antithrombin III levels in female patients. Table 7 summarizes the results and the criteria for normality of the different aggregation tests carried out in this study. We found no abnormality for the collagen, ristocetin, epinephrine or ADP 10 μηιοΐ/ΐ platelet aggregation (0/22). One patient however presented with spontaneous aggregation, three out of fifteen with 0.2 μηιοΐ/ΐ ADP aggregation and fifteen of the twenty two patients with increased 2 μιηοΐ/ΐ ADP aggregation. In table 8 we can see that the maximal amplitude (A max ) of the 2 μτηοΙ/1 ADP aggregation of the normal patient group with an A max of 35% hardly differs from the A max of the control group of healthy individuals (A max = 30%). The difference however between the abnormal patient group (A max = 77.5%) and the normal patient group was significant (p < 0.0001).
Discussion
This study was designed to investigate the basis of the thrombocytosis in patients with Crohn's disease and colitis ulcerosa, which is known to occur in patients with exacerbation of the disease (1, 12, 13) .
From the results of this study it seems clear that the degree of thrombocytosis is greater for females than for males, a fact that is consistent with earlier reports (14) of higher platelet counts for females in a reference population. The question arises as to the degree of thrombocytosis that can be considered as a prethrombotic factor. For this purpose we investigated platelet aggregation after induction with different stimuli. One patient showed spontaneous aggregation, three patients showed aggregation with 0.2 μηιοΐ/ΐ ADP, and fifteen patients showed enhanced aggregation with 2 μηιοΐ/l ADP. Taking account of the need for care in the handling and interpretation of aggregation tests, we can conclude that the platelets of 15/22 patients showed an unphysiologically strong in vitro reaction in the ADP 2 μηιοΐ/ΐ aggregation induction test, which can be considered as representing a prethrombotic state. This is in agreement with the observations of Lake et al. (4) , who reported increased platelet counts associated with abnormal platelet function in patients with bowel disease.
The platelet aggregation effect was of the same magnitude in males and females. This was not the case for fibrinogen, which showed a significant difference between males and females, and a significant increase in comparison with the reference group. Lee et al. (7) reported similar changes in fibrinogen in chronic ulcerative colitis. It is conceivable that high levels of fibrinogen may increase the risk of thrombus formation. Moreover, we know that elevation of fibrinogen increases blood viscosity, which may in turn further enhance the risk of thrombus formation.
In summary, it seems that, in our patient group, fibrinogen can be considered as a risk factor for the development of thrombosis, and to a greater degree in women than in men. In 22.7% of the patients, the increased thrombin-antithrombin III concentrations suggest the possibility of clotting activation, although the difference between the mean of the reference and the patient group is not significant on the 95% level. When the thrombin-antithrombin HI results were classified according to sex, the mean for males, but not that for females, showed a significant difference. Ghosh et al. (15) described patients with inflammatory bowel disease, decreased antithrombin III and a history of thrombosis, and speculated that their results were due to an increased consumption of antithrombin III. It can be concluded that coagulation activation occurs, at least in the male patients. This was clearly established by the results of the D-Dimer analysis. Both the fact that 68.2% of the overall results exceed the upper reference limit and the fact that the overall mean of the D-Dimer determinations was significantly enhanced in the patient group in relation to the reference group can be taken as evidence for the presence of a reactive fibrinolysis after preceeding coagulation in these patients. This is also suggested by the recent findings of Wakefieldti al., who reported that Crohn's disease is mediated by multifocal gastrointestinal infarction (19) . This is important for understanding the pathogenesis of Crohn's disease and its common clinical features. The strongest fibrinolysis effect was again found in the male patients, which is in full agreement with the previously mentioned thrombin-antithrombin III results for males and females. For the rest, it seems inconceivable at first sight, that the degree of fibrinolysis would be somewhat higher than expected from the thrombin-antithrombin III results. An acceptable explanation, however, could be that all the reactions caused by thrombin generation will ultimately result in the production of D-Dimers. Increased fibrinolytic activity was first described by Kwaan et al. (16, 17) in patients with active colitis, and Kondo et al. (18) later reported the same results. These investigators suggested some connection between hyperfibrinolysis and anal blood loss, and reported clinical improvement and reduction of blood loss after antifibrinolytic therapy.
In summary, our study suggests the presence of prethrombotic factors in the acute phase of inflammatory bowel disease, which might contribute to an increased risk of thrombosis, as also confirmed by de Jong et al. (9) . The activation of the fibrinolysis system in the acute phase of inflammatory bowel disease, as shown indirectly in this study by measurement of the DDimers, must be the result of increased plaminogen transformation. Plasmin is known to have -in addition to its main fibrinolytic function -the ability to activate collagenases, which in excess could adversely affect wound healing, a process undoubtedly needed in these patients. Thus, it may be worth reinvestigating and reconsidering the treatment of these patients with antifibrinolytic agents.
